Programmed Death-Ligand 1 Protein and Colorectal Cancer Patient Survival Rates in Hasan Sadikin Hospital Bandung
DOI:
https://doi.org/10.37275/bsm.v6i1.437Keywords:
PD-L1, Colorectal cancer, Survival rateAbstract
Background: According to the American Cancer Society, Colorectal Cancer (CRC) is the third leading cause of cancer death in men and women in the United States. In Indonesia, CRC ranks as the third most common malignancy in both men and women. Programmed death-ligand 1(PD-L1) is a trans-membrane receptor ligand and negative regulatory signal for T cells that is elevated in several tumors including CRC and binds to programmed death 1 (PD-1) on T cells, B cells, dendritic cells and natural killer T cells. PD-L1 expression was found in tumor cells and tumor cells that infiltrate immune cells in several malignancies, including CRC.
Methods: This study is a comparative analytic cross sectional study with consecutive sampling method. This study was conducted at Hasan Sadikin Hospital, Bandung from September to October 2021. Further statistical analysis was done SPSS version 25.0 for Windows (SPSS Inc., Chicago, Ill., USA).
Results: The total sample in this study was 50 subjects with colorectal cancer patients at RSHS. The number of CRC patients who expressed PD-L1 were 23 (46%) and 27 subjects (54%). The majority of cancer patient survival 2 Years was 38 subjects (76.0%) and survivors of more than 2 years was 12 subjects (24.0%).
Conclusion: There is no significant relationship between PD-L1 and survival rates in CRC patients.
Authors
- Vandra Bina Riyanda1*
- Reno Rudiman2
- Nurhayat Usman2
- 1Trainee Digestive Surgeon Department, Faculty of Medicine, Padjajaran University, Bandung, Indonesia
- 2Digestive Surgeon Department, Faculty of Medicine, Padjajaran University, Bandung, Indonesia
Corresponding author Vandra Bina Riyanda — vandrariyanda@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
